R1 RCM Inc. (NASDAQ:RCM) Receives Average Recommendation of “Moderate Buy” from Analysts

R1 RCM Inc. (NASDAQ:RCM) has received a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are presently covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $16.00.

A number of equities analysts have commented on the company. Morgan Stanley restated an “overweight” rating and set a $17.00 price objective on shares of R1 RCM in a research note on Monday, July 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price target on shares of R1 RCM in a research note on Tuesday, July 2nd. Robert W. Baird reiterated an “outperform” rating and set a $18.00 price objective on shares of R1 RCM in a research note on Tuesday, July 2nd. Truist Financial reissued a “hold” rating and issued a $16.00 target price on shares of R1 RCM in a report on Monday, April 1st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $19.00 price target on shares of R1 RCM in a report on Friday, June 28th.

Institutional Trading of R1 RCM

Hedge funds and other institutional investors have recently made changes to their positions in the company. Voss Capital LLC boosted its position in R1 RCM by 553.9% during the 4th quarter. Voss Capital LLC now owns 7,125,000 shares of the healthcare provider’s stock worth $75,311,000 after buying an additional 6,035,340 shares during the period. Norges Bank acquired a new stake in R1 RCM during the 4th quarter valued at approximately $42,539,000. P2 Capital Partners LLC raised its holdings in R1 RCM by 70,366.3% during the 4th quarter. P2 Capital Partners LLC now owns 3,535,294 shares of the healthcare provider’s stock worth $37,368,000 after purchasing an additional 3,530,277 shares during the last quarter. Boston Partners lifted its position in shares of R1 RCM by 4,976.6% in the 1st quarter. Boston Partners now owns 2,570,371 shares of the healthcare provider’s stock worth $32,784,000 after purchasing an additional 2,519,739 shares during the period. Finally, Sea Cliff Partners Management LP bought a new stake in shares of R1 RCM in the 4th quarter valued at $18,459,000. 61.10% of the stock is currently owned by institutional investors.

R1 RCM Trading Up 0.9 %

RCM stock opened at $13.43 on Friday. R1 RCM has a 52 week low of $8.87 and a 52 week high of $18.53. The company has a market capitalization of $5.66 billion, a PE ratio of -167.88 and a beta of 0.85. The company’s 50-day simple moving average is $12.51 and its 200 day simple moving average is $12.12. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.79 and a current ratio of 1.79.

R1 RCM (NASDAQ:RCM) last announced its earnings results on Wednesday, May 8th. The healthcare provider reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). R1 RCM had a negative return on equity of 1.16% and a negative net margin of 1.39%. The business had revenue of $603.90 million for the quarter, compared to analyst estimates of $612.88 million. The business’s revenue was up 10.7% on a year-over-year basis. As a group, sell-side analysts anticipate that R1 RCM will post -0.2 earnings per share for the current year.

About R1 RCM

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.